RecruitingPhase 1Phase 2NCT05697406

HP Pyruvate MRI in Cancers

Hyperpolarized 13-C Pyruvate MRI Surveillance of Multiple Cancers


Sponsor

University of Maryland, Baltimore

Enrollment

25 participants

Start Date

Jun 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Many human diseases are characterized by their ability to alter existing metabolic pathways and interrupt cellular processes. Cancer exploits the Warburg effect and utilizes greater glucose than normal cells and within this process uses anaerobic respiration, leading to increased conversion of pyruvate to lactate. This can be exploited by hyperpolarized imaging. Hyperpolarized 13C MRI imaging is an approach that utilizes a stable isotope of Carbon (13C) linked to pyruvate. MRI spectroscopy is used in conjunction with hyperpolarized 13C pyruvate in order to temporally detect pyruvate and its conversion to lactate in-vivo, in order to visualize downstream metabolic (glycolytic) activity secondary to the Warburg effect, which should be useful in detecting and characterizing tumors of various types. Hyperpolarized 13C pyruvate MR imaging has not been tested in most cancers. In this preliminary survey, we will test the hypothesis that hyperpolarized 13C pyruvate MR imaging can be used to image various cancers.


Eligibility

Min Age: 18 YearsMax Age: 88 Years

Inclusion Criteria3

  • Clinical tumor diagnosis
  • Patients with pre-existing MR imaging appointments
  • Must be able to undergo MR

Exclusion Criteria1

  • No tumor diagnosis

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHyperpolarized 13C-Pyruvate

Imaging tumors pre and post administration of hyperpolarized 13-C pyruvate injection.


Locations(1)

University of Maryland Medical Center

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05697406


Related Trials